Skip to main content


We're creating a new version of this page. See preview

  • Invited speaker presentation
  • Open Access

Clinical use of pharmacogenomics

  • 1
Retrovirology20129 (Suppl 1) :I2

  • Published:


  • Infectious Disease
  • Cancer Research
  • Disease Process
  • Bone Disease
  • Limited Impact

The expanding list of antiretroviral drugs, the increasing possibilities in therapy of HCV and other co-infections represent an attractive setting for individualized prescription. However, there has been considerable hype, and limited impact of pharmacogenetics in care.

The development of pharmacogenetic tools would be of interest considering the complexity of treatment, the cost, and the expectation of long-term exposure. It would also be desirable given the possibility of serious toxicity, but also treatment intolerance, cumulative toxicity or the unfavorable interaction of drugs and aging, metabolic, cardiovascular and bone disease processes.

This presentation will review available tests, the position of agencies on the inclusion of pharmacogenetic information in labels, and a perspective on developments in genomic medicine.

Authors’ Affiliations

University of Lausanne, Switzerland


© Telenti; licensee BioMed Central Ltd. 2012

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.